NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer

Pharma Times

7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK.

NICE has issued a final appraisal determination recommending MSD’s Keytruda (pembrolizumab) when used in combination with carboplatin and paclitaxel as an option for untreated metastatic squamous non-small-cell lung cancer in adults.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder